Drug delivery system for the clinical application of cytokines

将重组人LT包被免疫脂质体，在免疫脂质体上偶联单克隆抗a375抗体。这些免疫脂质体在体内和体外实验中对A375细胞均表现出较强的类细胞性。将小鼠IFN-Y与人LT包埋在抗A375结合的免疫脂质体中，从A375细胞植入后2天开始，每周2次给裸鼠注射免疫脂质体，与仅包埋人LT的免疫脂质体实验相比，细胞毒性明显增强。这些结果清楚地表明，lt免疫脂质体至少有一部分的细胞毒性是通过宿主动物的免疫系统发挥的。

Recombinant human LT was encapsulated into immunoliposomes on which monoclonal anti-A375 antibody was conjugated. These immunoliposomes showed stronger cytotoidcity toward A375 cells in in vitro experiments and also in vivo experiments. When mouse IFN-Y was encapsulated in anti-A375-conjugated immunoliposomes together with human LT and those immunoliposomes were administered into nude mice twice a week starting from 2 days after implantation of A375 cells, significantly stronger cytotoxicity was observed compared with the experiments using immunoliposomes in which only human LT was encapsulated. These results clearly indicated that at least a part of cytotoxicity of LT-immunoliposomes was exerted through the immune system of host animals.